Myriam P Hoyeck

Sep 26, 2024 | biorxiv.org | Lahari Basu |Myriam P Hoyeck |Lili Grieco-St-Pierre |Kelsea S McKay

AbstractCancer survivors have an increased risk of developing new-onset Type 2 diabetes compared to the general population. Moreover, patients treated with cisplatin, a commonly used chemotherapeutic agent, are more likely to develop metabolic syndrome and Type 2 diabetes compared to age- and sex-matched controls.

Feb 17, 2024 | biorxiv.org | Myriam P Hoyeck |Lahari Basu |Rayanna Merhi |Erin van Zyl

AbstractAims/hypothesis: The aryl hydrocarbon receptor (AhR) pathway is involved in cellular responses to a broad range of external stressors, making it an excellent candidate for understanding the interaction between environmental factors and type 2 diabetes risk. Studies suggest deleting or downregulating AhR protects against metabolic dysfunction in high-fat diet (HFD) fed mice; however, the contribution of downstream AhR targets in driving this phenotype remains unexamined.